CN107252492A - 治疗糖尿病和/或促进胰岛移植后存活的方法 - Google Patents

治疗糖尿病和/或促进胰岛移植后存活的方法 Download PDF

Info

Publication number
CN107252492A
CN107252492A CN201710440085.9A CN201710440085A CN107252492A CN 107252492 A CN107252492 A CN 107252492A CN 201710440085 A CN201710440085 A CN 201710440085A CN 107252492 A CN107252492 A CN 107252492A
Authority
CN
China
Prior art keywords
seq
smad7
diabetes
cells
antisense oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710440085.9A
Other languages
English (en)
Chinese (zh)
Inventor
乔凡尼·蒙特利尔
彼得·布赫瓦尔德
卢卡·因弗拉迪
安东内洛·派勒吉
卡米洛·利科迪
爱丽丝·多美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuo Geer Pharmaceutical Co Ltd
University of Miami
Original Assignee
Nuo Geer Pharmaceutical Co Ltd
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuo Geer Pharmaceutical Co Ltd, University of Miami filed Critical Nuo Geer Pharmaceutical Co Ltd
Publication of CN107252492A publication Critical patent/CN107252492A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201710440085.9A 2012-04-18 2013-04-18 治疗糖尿病和/或促进胰岛移植后存活的方法 Pending CN107252492A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261625904P 2012-04-18 2012-04-18
US61/625,904 2012-04-18
CN201380020520.2A CN104487574B (zh) 2012-04-18 2013-04-18 治疗糖尿病和/或促进胰岛移植后存活的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380020520.2A Division CN104487574B (zh) 2012-04-18 2013-04-18 治疗糖尿病和/或促进胰岛移植后存活的方法

Publications (1)

Publication Number Publication Date
CN107252492A true CN107252492A (zh) 2017-10-17

Family

ID=48326412

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710440085.9A Pending CN107252492A (zh) 2012-04-18 2013-04-18 治疗糖尿病和/或促进胰岛移植后存活的方法
CN201380020520.2A Expired - Fee Related CN104487574B (zh) 2012-04-18 2013-04-18 治疗糖尿病和/或促进胰岛移植后存活的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380020520.2A Expired - Fee Related CN104487574B (zh) 2012-04-18 2013-04-18 治疗糖尿病和/或促进胰岛移植后存活的方法

Country Status (14)

Country Link
US (3) US10081809B2 (https=)
EP (1) EP2839004B1 (https=)
JP (2) JP6348484B2 (https=)
KR (1) KR20150003824A (https=)
CN (2) CN107252492A (https=)
AU (1) AU2013249191B2 (https=)
CA (1) CA2870547A1 (https=)
DK (1) DK2839004T3 (https=)
ES (1) ES2732252T3 (https=)
IN (1) IN2014DN08158A (https=)
MX (1) MX370149B (https=)
NZ (1) NZ630914A (https=)
RU (1) RU2667960C2 (https=)
WO (1) WO2013158868A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
RU2593939C2 (ru) 2008-11-13 2016-08-10 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
JP6389122B2 (ja) 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
ES2704092T3 (es) * 2014-04-30 2019-03-14 Procter & Gamble Composición limpiadora
AU2015257589A1 (en) 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3165593B1 (en) * 2015-10-29 2019-01-23 The Procter and Gamble Company Liquid detergent composition
EP3162878A1 (en) * 2015-10-29 2017-05-03 The Procter and Gamble Company Liquid detergent composition
EP3420082A4 (en) 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION
US11584935B2 (en) * 2018-05-08 2023-02-21 University Of Miami Materials and methods for the delivery of therapeutic nucleic acids to tissues
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087920A1 (en) * 2003-04-02 2004-10-14 Giuliani International Limited Antisense oligonucleotides (odn) against smad7 and uses in medical field thereof
WO2005014011A1 (en) * 2003-08-11 2005-02-17 Giuliani S.P.A. Use of smad 7 antisense oligonucleotides (odn) for the treatment of diseases mediated by the nuclear transcription factor nf-kb

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
EP1456380B1 (en) 2001-11-02 2012-04-18 Giuliani International Limited Smad7 inhibitors for the treatment of cns diseases
AU2004263830B2 (en) * 2003-06-13 2008-12-18 Alnylam Pharmaceuticals, Inc. Double-stranded ribonucleic acid with increased effectiveness in an organism
GB0326778D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
RU2434942C2 (ru) * 2004-09-28 2011-11-27 Кварк Фармасьютикалс, Инк. Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний
AU2005288522B2 (en) 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
WO2007039151A1 (en) * 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
ES2686708T3 (es) * 2008-04-18 2018-10-19 Baxter International Inc. Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición
RU2593939C2 (ru) * 2008-11-13 2016-08-10 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
JP6389122B2 (ja) 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
AU2014229985B2 (en) 2013-03-15 2018-12-13 Nogra Pharma Limited Methods of treating colorectal cancer
AU2015257589A1 (en) 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
EP3213070A2 (en) 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
CA3000569A1 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
WO2017144689A1 (en) 2016-02-24 2017-08-31 Nogra Pharma Limited Methods of treating celiac disease using smad7 inhibition
WO2018122376A1 (en) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087920A1 (en) * 2003-04-02 2004-10-14 Giuliani International Limited Antisense oligonucleotides (odn) against smad7 and uses in medical field thereof
WO2005014011A1 (en) * 2003-08-11 2005-02-17 Giuliani S.P.A. Use of smad 7 antisense oligonucleotides (odn) for the treatment of diseases mediated by the nuclear transcription factor nf-kb

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NORA G. SMART ET AL.: "Conditional Expression of Smad7 in Pancreatic-β Cells Disrupts TGF-β Signaling and Induces Reversible Diabetes Mellitus", 《PLOS BIOLOGY》 *

Also Published As

Publication number Publication date
AU2013249191B2 (en) 2019-01-03
MX2014012650A (es) 2015-04-08
CN104487574A (zh) 2015-04-01
AU2013249191A1 (en) 2014-10-09
US20150315573A1 (en) 2015-11-05
RU2014146170A (ru) 2016-06-10
US10081809B2 (en) 2018-09-25
CN104487574B (zh) 2017-07-07
EP2839004B1 (en) 2019-06-12
EP2839004A1 (en) 2015-02-25
JP2015514778A (ja) 2015-05-21
JP6348484B2 (ja) 2018-06-27
RU2667960C2 (ru) 2018-09-25
KR20150003824A (ko) 2015-01-09
US20190136237A1 (en) 2019-05-09
WO2013158868A1 (en) 2013-10-24
JP2018131468A (ja) 2018-08-23
ES2732252T3 (es) 2019-11-21
US20200239884A1 (en) 2020-07-30
IN2014DN08158A (https=) 2015-05-01
NZ630914A (en) 2017-01-27
CA2870547A1 (en) 2013-10-24
DK2839004T3 (da) 2019-07-01
US10443056B2 (en) 2019-10-15
HK1207117A1 (en) 2016-01-22
MX370149B (es) 2019-12-03

Similar Documents

Publication Publication Date Title
CN104487574B (zh) 治疗糖尿病和/或促进胰岛移植后存活的方法
KR102021688B1 (ko) 아포지방단백질 ｃｉｉｉ （ａｐｏｃｉｉｉ） 발현의 조정
KR102169899B1 (ko) 지질단백질 리파제 결핍 (lpld) 모집단에서 아포지질단백질 c-iii (apociii) 발현의 조절
US10006029B2 (en) Methods of treating colorectal cancer
CN105008394A (zh) 治疗结肠直肠癌的方法
JP2021106625A (ja) Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法
CN107405358A (zh) 调节脂肪代谢障碍群体中的载脂蛋白c‑iii(apociii)表达
Mahjoubin-Tehran et al. Decoys as potential therapeutic tools for diabetes
EP2349315A1 (en) Regulation of lymphocytes and uses therefor
JP2023526453A (ja) 膵炎の治療及び膵臓がんの予防のための方法
US20210290595A1 (en) Gfi1 inhibitors for the treatment of hyperglycemia
US20110034381A1 (en) Methods for Therapeutic Treatment of Benign Prostatic Hypertrophy (BPH)
HK1207117B (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
Eissa et al. Modulating the Interleukin-5 Response in Asthma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20210409